Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Aerosolized iloprost in CREST syndrome related pulmonary hypertension
Autore:
Launay, D; Hachulla, E; Hatron, PY; Goullard, L; Onimus, T; Robin, S; Fauchais, AL; Queyrel, V; Michon-Pasturel, U; Hebbar, M; Saulnier, F; Devulder, B;
Indirizzi:
Reg Univ Hosp, Dept Internal Med, Lille, France Reg Univ Hosp Lille France Univ Hosp, Dept Internal Med, Lille, France Reg Univ Hosp, Dept Funct Cardiac Explorat, Lille, France Reg Univ Hosp Lille France , Dept Funct Cardiac Explorat, Lille, France Reg Univ Hosp, Dept Funct Resp Explorat, Lille, France Reg Univ Hosp Lille France osp, Dept Funct Resp Explorat, Lille, France Reg Univ Hosp, Med Intens Care Unit, Lille, France Reg Univ Hosp Lille France iv Hosp, Med Intens Care Unit, Lille, France
Titolo Testata:
JOURNAL OF RHEUMATOLOGY
fascicolo: 10, volume: 28, anno: 2001,
pagine: 2252 - 2256
SICI:
0315-162X(200110)28:10<2252:AIICSR>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
SYSTEMIC-SCLEROSIS; PROSTACYCLIN; SCLERODERMA; EPOPROSTENOL; SECONDARY; TRIAL; TERM;
Keywords:
scleroderma; CREST; pulmonary hypertension; iloprost aerosol;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Hachulla, E CHRU, Hop Claude Huriez, Med Interna Serv, 1 Pl Verdun, F-59037 Lille, France CHRU 1 Pl Verdun Lille France F-59037 , F-59037 Lille, France
Citazione:
D. Launay et al., "Aerosolized iloprost in CREST syndrome related pulmonary hypertension", J RHEUMATOL, 28(10), 2001, pp. 2252-2256

Abstract

Objective. To assess the outcome of patients with CREST syndrome associated severe pulmonary hypertension treated by aerosolized iloprost in a noncomparative study. Methods. Five patients with CREST syndrome associated severe pulmonary hypertension were treated with 100 mug/day of aerosolized iloprost. New York Heart Association functional class and exercise tolerance (6 min walk, test)were assessed at baseline, after one month, and then every 6 months. A right heart catheterization was performed at baseline in all but one patient. Systolic pulmonary artery pressure (PAP) was measured with Doppler echocardiography after one month and every 6 months. Results. The mean followup was 13.2 +/- 8.8 months (median 6, range 6-24). Subjective quality of life improved in all patients. NYHA functional classdecreased from Class III to II in 3 patients, from Class III to I in one patient, and from Class IV to III in one patient. At 6 months, the distance walked in 6 min had increased from 352 +/- 48 to 437 +/- 56 in (p = 0.06). At one month the mean Systolic PAP was 58 +/- 13 vs 81 +/- 9 min Hg at baseline (p = 0.04). At 6 months the mean systolic PAP was 57 +/- 13 min Hg (p = 0.06). The improvement of both clinical and hemodynamic status was maintained in the 2 patients treated for 2 years. Neither adverse effects nor need to increase the daily dose of iloprost were observed. One patient died ofright heart failure and one patient did not experience any improvement of exercise tolerance and hemodynamics. Conclusion. Aerosolized iloprost might be potentially useful as treatment for CREST syndrome associated pulmonary hypertension. However, patients whocould benefit from this treatment will probably have to undergo careful criteria selection.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/21 alle ore 03:40:04